Inhibitory effect of somatostatin-28 on pancreatic polypeptide, glucagon and insulin secretion in normal man

We have compared the effects of equimolar doses of intravenous somatostatin-28 (SS-28) and somatostatin-14 (SS-14) (250 micrograms and 125 micrograms, respectively) on the secretion of pancreatic polypeptide (PP), glucagon and insulin evoked by a protein-rich meal in normal subjects. Both peptides r...

Full description

Saved in:
Bibliographic Details
Published inHormone and metabolic research Vol. 15; no. 8; p. 363
Main Authors Marco, J, Correas, I, Zulueta, M A, Vincent, E, Coy, D H, Comaru-Schally, A M, Schally, A V, Rodríguez-Arnao, M D, Gómez-Pan, A
Format Journal Article
LanguageEnglish
Published Germany 01.08.1983
Subjects
Adult
Blood Glucose - metabolism
Fasting
Food
Glucagon - metabolism
Humans
Insulin - metabolism
Insulin Secretion
Kinetics
Male
Pancreatic Polypeptide - metabolism
Somatostatin
Somatostatin-28
Online AccessGet more information

Cover

More Information
Summary:We have compared the effects of equimolar doses of intravenous somatostatin-28 (SS-28) and somatostatin-14 (SS-14) (250 micrograms and 125 micrograms, respectively) on the secretion of pancreatic polypeptide (PP), glucagon and insulin evoked by a protein-rich meal in normal subjects. Both peptides reduced the fasting plasma levels of these hormones and completely abolished their responses to the alimentary stimulus; in addition, they caused an early decrease of plasma glucose followed by a hyperglycemic phase. As compared to SS-14, SS-28 elicited a longer-lasting inhibition of PP and insulin secretion and displayed greater hypo- and hyperglycemic effects. A somatostatin-like component, similar to SS-28, has been identified in pancreatic extracts as well as in peripheral plasma. Thus, it might be hypothesized that this peptide plays a role in the control of pancreatic hormone release.
ISSN:0018-5043
1439-4286
DOI:10.1055/s-2007-1018725